Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 18/20 | 0.74 |
| ▸ | THRA | P10827 | 3/20 | 0.55 |
| ▸ | THRB | P10828 | 3/20 | 0.55 |
| ▸ | BBOX1 | O75936 | 1/20 | 0.55 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.55 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.55 |
| ▸ | ASPH | Q12797 | 1/20 | 0.55 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.55 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18121935 | 0.88 | EGLN1 (0.64) | EGLN1THRATHRBBBOX1SLC6A2 | |
| SCHEMBL18121914 | 0.88 | EGLN1 (0.69) | EGLN1THRATHRBBBOX1SLC6A2 | |
| SCHEMBL20109770 | 0.87 | EGLN1 (0.70) | EGLN1THRATHRBBBOX1SLC6A2 | |
| SCHEMBL19808869 | 0.85 | EGLN1 (1.00) | EGLN1THRATHRBBBOX1SLC6A2 | |
| SCHEMBL20109773 | 0.85 | EGLN1 (0.71) | EGLN1THRATHRBBBOX1SLC6A2 | |
| SCHEMBL18121915 | 0.84 | EGLN1 (0.71) | EGLN1THRATHRBBBOX1SLC6A2 | |
| SCHEMBL20110890 | 0.84 | EGLN1 (0.72) | EGLN1THRATHRBBBOX1SLC6A2 | |
| SCHEMBL19895144 | 0.83 | EGLN1 (0.51) | EGLN1 | |
| SCHEMBL20109777 | 0.82 | EGLN1 (0.62) | EGLN1THRATHRBBBOX1SLC6A2 | |
| SCHEMBL20109769 | 0.81 | EGLN1 (0.60) | EGLN1THRATHRBFTO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9994566-B2 | Compound of 5-hydroxyl-1,7-naphthyridine substituted by aryl or heteroaryl, preparation method thereof and pharmaceutical use thereof | SHENYANG SUNSHINE PHARMACEUTICAL CO. LTD. (CN) | 2018-06-12 | — | — | US | disclosed |
| US-9994566-B2 | Compound of 5-hydroxyl-1,7-naphthyridine substituted by aryl or heteroaryl, preparation method thereof and pharmaceutical use thereof | SHENYANG SUNSHINE PHARMACEUTICAL CO. LTD. (CN) | 2018-06-12 | — | — | US | disclosed |
| US-20180118738-A1 | COMPOUND OF 5-HYDROXYL-1,7-NAPHTHYRIDINE SUBSTITUTED BY ARYL OR HETEROARYL, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE THEREOF | SHENYANG SUNSHINE PHARMACEUTICAL CO., LTD. (CN) | 2018-05-03 | — | — | US | disclosed |
| US-20180118738-A1 | COMPOUND OF 5-HYDROXYL-1,7-NAPHTHYRIDINE SUBSTITUTED BY ARYL OR HETEROARYL, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE THEREOF | SHENYANG SUNSHINE PHARMACEUTICAL CO., LTD. (CN) | 2018-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180118738-A1 | COMPOUND OF 5-HYDROXYL-1,7-NAPHTHYRIDINE SUBSTITUTED BY ARYL OR HETEROARYL, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE THEREOF | HIF1AN, EGLN3, EGLN2 | EGLN1 7/4885THRA 1568/4885THRB 2076/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.